Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression

NCT07176182 · tracked via the Priya Life Science China tracker

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University

Phase

Phase 2

Started

2026-03-20

Last updated

2026-05-26

Condition(s) studied

Rectal Cancer PatientsRectal Cancer Stage IIRectal Cancer Stage III

Investigational drug(s) / intervention(s)

mFOLFOX regimen combined with Citrus Flavone Tablets (Alvenor) neoadjuvant treatment group →mFOLFOX regimen neoadjuvant therapy group →

mFOLFOX regimen combined with Citrus Flavone Tablets (Alvenor) neoadjuvant treatment group: The trial evaluates a regimen combining mFOLFOX chemotherapy with citrus flavonoid tablets (Alvenor) for neoadjuvant therapy (pre-surgery) and postoperative adjuvant therapy. Treatment Protocol Preoperative (4-6 cycles) and Postoperative (6-8 cycles): Each 14-day cycle includes: Oxaliplatin: 85 mg/m² via 180-minute intravenous infusion on Day 1. Leucovorin: 400 mg/m² via 120-minute intravenous infusion on Day 1. 5-Fluorouracil: 2400 mg/m² via continuous intravenous infusion over 46 hours. Citrus flavonoid tablets (Alvenor) : 500 mg orally three times daily (Days 1-14), administered with or without the chemotherapy regimen (depending on group assignment).

mFOLFOX regimen neoadjuvant therapy group: The trial evaluates a regimen combining mFOLFOX chemotherapy with citrus flavonoid tablets (Alvenor) for neoadjuvant therapy (pre-surgery) and postoperative adjuvant therapy. Treatment Protocol Preoperative (4-6 cycles) and Postoperative (6-8 cycles): Each 14-day cycle includes: Oxaliplatin: 85 mg/m² via 180-minute intravenous infusion on Day 1. Leucovorin: 400 mg/m² via 120-minute intravenous infusion on Day 1. 5-Fluorouracil: 2400 mg/m² via continuous intravenous infusion over 46 hours.

Study summary

This study is a prospective, multicenter, open-label, randomized controlled Phase II clinical trial enrolling patients with locally advanced rectal cancer who tested positive for YWHAB (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase-activating protein β) prior to surgery. The trial aims to evaluate the efficacy of combining the mFOLFOX chemotherapy regimen with citrus flavonoid tablets (Aimilang) for neoadjuvant (preoperative) treatment.

Treatment Regimen 4-6 cycles preoperatively, with each cycle lasting 14 days.

Translated with DeepL.com (free version)

Oxaliplatin: 85 mg/m² via 180-minute intravenous infusion on Day 1.

Leucovorin: 400 mg/m² via 120-minute intravenous infusion on Day 1.

5-Fluorouracil: 2400 mg/m² via continuous intravenous infusion over 46 hours.

Citrus flavonoid tablets (Aimailang) : 500 mg orally twice times daily (Days 1-14), administered with or without the chemotherapy regimen (depending on group assignment).

Key Trial Design Features Dose Adjustments: Permitted during the trial based on patient tolerance.

Discontinuation Criteria:

Patients with disease progression during neoadjuvant therapy will cease study treatment and proceed to surgery or alternative therapies per local guidelines.

Surgery may be initiated early if patients cannot tolerate the planned 6 cycles of neoadjuvant therapy.

Patients receiving non-protocol anticancer therapies preoperatively will be withdrawn from the study.

Postoperative Management:

Post-treatment plans (e.g., continuation of mFOLFOX + Aimailang) are determined by the investigator.

Control Group Restriction: Patients in the control arm are not permitted to self-administer citrus flavonoid tablets (Aimailang) during the trial. Any requirement for this medication must be discussed with the treating physician, who will decide on alternative therapies or trial withdrawal.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria 1. Histopathologically confirmed rectal adenocarcinoma; all other histologic subtypes are excluded. Presence of hemorrhoids confirmed by colonoscopy or clinical physical examination. 2. Radiographically measurable or clinically evaluable rectal tumor lesion; clinical pathologic stage T2N+ or T3-4aAnyN, M0. Clinical staging is determined by physical examination, contrast-enhanced chest and abdominopelvic CT, and pelvic MRI. For patients with MRI contraindications, staging is performed with contrast-enhanced pelvic CT plus transrectal ultrasound. Staging adheres to the 9th AJCC TNM Staging System (Appendix 1). 3. Pelvic MRI confirms the tumor is not adherent to the mesorectal fascia (MRF-negative), defined as a tumor-MRF distance ≥ 2 mm (tumor distance \< 2 mm is defined as MRF involvement). 4. ectal cancer tumor specimens demonstrate high YWHAB expression by immunohistochemistry. 5. Age 18-75 years at the time of informed consent. 6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Appendix 3). 7. No prior systemic anticancer therapy for rectal cancer, including cytotoxic chemotherapy, immune checkpoint inhibitors, molecular targeted agents, or endocrine therapy. 8. Adequate organ function with screening laboratory parameters meeting the following criteria: * White blood cell count ≥ 3 × 10⁹/L * Absolute neutrophil count ≥ 1.5 × 10⁹/L * Platelet count ≥ 75 × 10⁹/L * Total bilirubin ≤ 1.5 × upper limit of normal (ULN) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN * Serum creatinine ≤ 1.5 × ULN 9. Females of childbearing potential must have a negative serum pregnancy test within 3 days prior to initiation of study treatment and agree to use a highly effective, medically acceptable contraceptive method (e.g., intrauterine device, combined oral contraceptives, barrier methods) throughout the study and for 3 months after the last study drug administration. 10. Male patients with partners of childbearing potential must practice effective contraception during the study and for 3 months following the last study drug administration. 11. The patient voluntarily provides written informed consent and is willing and able to comply with all scheduled study visits, treatment administration, laboratory assessments, and protocol-specified procedures.

Primary outcome measure(s)

Tumor downstaging rate (to ypTNM stage 0-I) — Perioperative，2 weeks after surgery
The proportion of patients with locally advanced rectal cancer who, after receiving neoadjuvant chemotherapy with mFOLFOX or mFOLFOX plus Citrus flavonoid tablets (Aimailang), were downstaged to ypTNM stage 0-I based on postoperative surgical specimens.

Trial sites (1)

Facility	City	Region	Status
The Sixth Affiliated Hospital of Sun Yat-sen University	Guangzhou	Guangdong	Recruiting

More Sixth Affiliated Hospital, Sun Yat-sen University trials in China

Reducing the Resection Range After Neoadjuvant Therapy for Locally Advanced Upper Rectal and Rectosigmoid Junction Cancers Active, not recruiting

Preoperative Oral Midazolam to Postoperative Pain Relief in Sleep Disturbance or Anxiety Patients With Colorectal Cancer Recruiting

A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial) Recruiting

Node-Sparing Short-Course Radiotherapy Plus First-Line Therapy and PD-1 Inhibitor in Unresectable/Metastastic pMMR/MSS Gastric Cancer (MODIFI-GC) Starting soon

ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer Recruiting

Other trials for the same condition

Bovine Reinforcement in Stomach, Colorectal and Lung Operation Recruiting

Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial Recruiting

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01） Recruiting

Selective Total Mesorectal Excision Based on Intra-Operative Frozen Section From Local Excision in Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy Recruiting

Application of Precision Partial Intersphincteric Resection (PPISR) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07176182 on ClinicalTrials.gov ↗ ← All trials in China